Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer

Detalhes bibliográficos
Principais autores:	Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H
Formato:	Journal article
Publicado em:	2004

Registros relacionados